{
    "info": {
        "nct_id": "NCT05204862",
        "official_title": "A Phase 1/2 Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TU2218, an Oral TGFβR Inhibitor, Administered Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors",
        "inclusion_criteria": "* Males and females at least 18 years of age at the time of consent (ie, screening), or according to local regulatory requirement if the legal age for consenting for study participation is more than 18 years.\n* Life expectancy ≥12 weeks as judged by the Investigator.\n* Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; except for Phase1a that can enroll patients with either measurable and/or non-measurable disease.\n* Eastern Cooperative Oncology Group (ECOG) 0 or 1.\n* Able to swallow capsules.\n* Histologically or cytologically documented advanced solid tumor for which no effective standard therapy exists, or standard therapy has failed (Phase 1a).\n* Histologically or cytologically documented advanced solid tumor for which no effective standard therapy exists, and for which standard therapy containing an anti-PD-(L)1 agent has failed after an initial response or stabilization of at least 4-month duration (Phase 1b and 2a).\n* Adequate hematological function, coagulation defined by:\n\n  1. Absolute neutrophil count ≥1,500 cells/μL\n  2. Platelet count ≥100,000/μL\n  3. Hemoglobin ≥9.0 g/dL\n  4. International normalized ratio <1.5 × the upper limit of normal (ULN)\n* Adequate hepatic and renal functions defined by:\n\n  1. Total bilirubin ≤1.5 × ULN\n  2. AST and ALT ≤3 × ULN; if liver metastases are present, then ≤5 × ULN is allowed\n  3. Estimated creatinine clearance >60 mL/min according to the Cockcroft-Gault formula\n* Able to understand and to comply with all protocol requirements, instructions, and restrictions.\n* QT interval corrected using Fridericia's formula (QTcF) interval ≤460 msec on screening ECG.\n* Normal ejection fraction (within the reference range of the institution).\n* A washout period of 4 weeks for any biologic material and a minimum of 5 half-lives for any chemotherapy is required prior to the start of treatment with resolution of any toxicity to maximum Grade 1 (except alopecia)\n* Completion of radiotherapy at least 14 days prior to the start of treatment with resolution of any toxicity to maximum Grade 1\n* Female patients of childbearing potential must have a negative serum pregnancy test within 7 days of the first administration of study treatment. For the purpose of this study, female patients of childbearing potential are defined as all female after puberty unless they are postmenopausal for at least 1 year, or are surgically sterile (hysterectomy or bilateral oophorectomy or tubal ligation)\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Myocardial infarction within 6 months prior to screening, or pericardial effusion.\n* History of cardiac or aortic surgery within 6 months prior to screening.\n* Unstable angina pectoris, cerebrovascular accident, transient ischemic attack, or symptomatic pulmonary embolism; deep venous thrombosis; arterial occlusive disease in the past 12 months.\n* Congestive heart failure of New York Heart Association class III/IV.\n* Major arrhythmia or abnormalities identified by ECG per Investigator's judgment.\n* Uncontrolled hypertension (as defined by systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg) during the screening period.\n* Elevated troponin 1 levels (Grade 3) at screening or known to have persistently elevated brain natriuretic peptide.\n* Active and clinically significant bacterial, fungal, or viral infection, including active or known history of hepatitis B virus (defined as hepatitis B surface antigen [HbsAg] reactive), or known active hepatitis C virus (defined as hepatitis C virus ribonucleic acid [qualitative] is detected), known human immunodeficiency virus or acquired immunodeficiency syndrome related illness. However, an inactive hepatitis B virus carrier can be enrolled\n* Current or history of interstitial pneumonitis.\n* Uncontrolled metastatic disease to the brain or central nervous system, massive uncontrolled effusions (pleural, pericardial, peritoneal), pulmonary lymphangitis, and over 50% liver involvement that is at the discretion of the Investigator. Note: Pleural effusion should be defined by Investigator's discretion.\n* Known history of difficulty swallowing, malabsorption or other conditions that may reduce absorption of the product.\n* Received prior treatment targeting the signaling pathway of TGF-β.\n* Tumor that compresses or invades major blood vessels or tumor cavitation that in the opinion of the Investigator is likely to bleed.\n* History of severe bleeding. Unable to stop anticoagulation therapy with heparin, low molecular weight heparin, vitamin K antagonists, antiplatelet agents, or factor Xa inhibitors throughout the study and for at least 28 days after the last administration of study treatment.\n* Regular use of aspirin (>325mg/day) or other non-steroidal anti-inflammatory drugs with antiplatelet activity or treatment with dipyramidole, ticlopidine, clopidogrel, or cilostazol within 10 days of first administration of study treatment.\n* Moderate or severe heart valve function defect including moderate or severe valve stenosis or regurgitation.\n* Evidence or history of septal aneurysm, other heart aneurysm, or any aneurysm of the major vessels.\n* Active infection requiring systemic antibiotic therapy.\n* Receipt of any live vaccine or live-attenuated vaccine within 30 days prior to the first drug administration and while participating the study.\n* Unable to unwilling to stop use of strong inhibitors of CYP1A2, CYP2C8, and CYP3A4, and strong inhibitors of P-gp and BCRP at least 8 days prior to study entry (Day 1) or within all dose escalation cohorts.\n* Unable or unwilling to stop use of gastric pH elevating agents including proton pump inhibitors, H2-recpetor antagonists and antacide at least 8 days prior to study entry (Day 1) or within all dose escalation cohorts.\n* Unwilling to stop use of herbal supplements or traditional herbal medicines.\n* Known substance abuse concurrent treatment with non-permitted drugs.\n* Known history, or suspected hypersensitivity to any excipients of the clinical study drugs.\n* Undergone major surgeries within 28 days of first dosing, or have a planned surgery during the study period.\n* Female patients who are breastfeeding.\n* Female patients must not be pregnant or at risk to become pregnant during the study. Fertile male and female patients must agree to use an effective barrier method of birth control to avoid pregnancy (for female patients a double-barrier method of contraception, for male patients a condom with spermicide) or total abstinence from the time of providing informed consent until 30 days after the last administration of TU2218.\n* Any other serious medical condition which in the Investigator's opinion would preclude safe participation in the study.\n\nFor Anti PD1 antibody combination therapy part:\n\n* Unable to stop chronic systemic steroid therapy or any other immunosuppressive mediacation\n* Use of oral, inhaled, or topical corticosteroid, at doses > 10mg/day prednisolone or equivalent and the dose must be stable over 4 weeks prior to Day1 of Cycle1.\n* Active autoimmune disease or history of autoimmune disease, except vitiligo, hypothyroidism, or resolved childhood asthma/atropy\n* Known tolerance to an anti-PD(L)1 agent during prior exposure",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Able to swallow capsules.",
            "criterions": [
                {
                    "exact_snippets": "Able to swallow capsules",
                    "criterion": "ability to swallow capsules",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Able to understand and to comply with all protocol requirements, instructions, and restrictions.",
            "criterions": [
                {
                    "exact_snippets": "Able to understand ... all protocol requirements, instructions, and restrictions.",
                    "criterion": "ability to understand protocol requirements, instructions, and restrictions",
                    "requirements": [
                        {
                            "requirement_type": "cognitive ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Able ... to comply with all protocol requirements, instructions, and restrictions.",
                    "criterion": "ability to comply with protocol requirements, instructions, and restrictions",
                    "requirements": [
                        {
                            "requirement_type": "compliance ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* QT interval corrected using Fridericia's formula (QTcF) interval ≤460 msec on screening ECG.",
            "criterions": [
                {
                    "exact_snippets": "QT interval corrected using Fridericia's formula (QTcF) interval ≤460 msec on screening ECG",
                    "criterion": "QTcF interval",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 460,
                                "unit": "msec"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* A washout period of 4 weeks for any biologic material and a minimum of 5 half-lives for any chemotherapy is required prior to the start of treatment with resolution of any toxicity to maximum Grade 1 (except alopecia)",
            "criterions": [
                {
                    "exact_snippets": "A washout period of 4 weeks for any biologic material",
                    "criterion": "biologic material washout period",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "a minimum of 5 half-lives for any chemotherapy is required prior to the start of treatment",
                    "criterion": "chemotherapy washout period",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 5,
                                "unit": "half-lives"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "resolution of any toxicity to maximum Grade 1 (except alopecia)",
                    "criterion": "toxicity resolution",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "Grade"
                            }
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": "alopecia"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female patients of childbearing potential must have a negative serum pregnancy test within 7 days of the first administration of study treatment. For the purpose of this study, female patients of childbearing potential are defined as all female after puberty unless they are postmenopausal for at least 1 year, or are surgically sterile (hysterectomy or bilateral oophorectomy or tubal ligation)",
            "criterions": [
                {
                    "exact_snippets": "Female patients of childbearing potential must have a negative serum pregnancy test within 7 days of the first administration of study treatment.",
                    "criterion": "serum pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days before first administration of study treatment"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "female patients of childbearing potential are defined as all female after puberty unless they are postmenopausal for at least 1 year, or are surgically sterile (hysterectomy or bilateral oophorectomy or tubal ligation)",
                    "criterion": "childbearing potential status",
                    "requirements": [
                        {
                            "requirement_type": "definition",
                            "expected_value": "female after puberty unless postmenopausal for at least 1 year or surgically sterile (hysterectomy or bilateral oophorectomy or tubal ligation)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Total bilirubin ≤1.5 × ULN",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin ≤1.5 × ULN",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate hematological function, coagulation defined by:",
            "criterions": [
                {
                    "exact_snippets": "Adequate hematological function",
                    "criterion": "hematological function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "coagulation defined by",
                    "criterion": "coagulation function",
                    "requirements": [
                        {
                            "requirement_type": "definition",
                            "expected_value": "as defined by protocol (details not provided in this line)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Platelet count ≥100,000/μL",
            "criterions": [
                {
                    "exact_snippets": "Platelet count ≥100,000/μL",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "/μL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Hemoglobin ≥9.0 g/dL",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin ≥9.0 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9.0,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Normal ejection fraction (within the reference range of the institution).",
            "criterions": [
                {
                    "exact_snippets": "Normal ejection fraction (within the reference range of the institution)",
                    "criterion": "ejection fraction",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "within the reference range of the institution"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; except for Phase1a that can enroll patients with either measurable and/or non-measurable disease.",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1",
                    "criterion": "disease measurability",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": "measurable as defined by RECIST v1.1"
                        }
                    ]
                },
                {
                    "exact_snippets": "Phase1a that can enroll patients with either measurable and/or non-measurable disease",
                    "criterion": "disease measurability (Phase 1a)",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": [
                                "measurable",
                                "non-measurable"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. AST and ALT ≤3 × ULN; if liver metastases are present, then ≤5 × ULN is allowed",
            "criterions": [
                {
                    "exact_snippets": "AST and ALT ≤3 × ULN",
                    "criterion": "AST level",
                    "requirements": [
                        {
                            "requirement_type": "maximum value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "AST and ALT ≤3 × ULN",
                    "criterion": "ALT level",
                    "requirements": [
                        {
                            "requirement_type": "maximum value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "if liver metastases are present, then ≤5 × ULN is allowed",
                    "criterion": "AST level (with liver metastases)",
                    "requirements": [
                        {
                            "requirement_type": "maximum value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "if liver metastases are present, then ≤5 × ULN is allowed",
                    "criterion": "ALT level (with liver metastases)",
                    "requirements": [
                        {
                            "requirement_type": "maximum value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate hepatic and renal functions defined by:",
            "criterions": [
                {
                    "exact_snippets": "Adequate hepatic ... functions",
                    "criterion": "hepatic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate ... renal functions",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Males and females at least 18 years of age at the time of consent (ie, screening), or according to local regulatory requirement if the legal age for consenting for study participation is more than 18 years.",
            "criterions": [
                {
                    "exact_snippets": "Males and females",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "allowed_values",
                            "expected_value": [
                                "male",
                                "female"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "at least 18 years of age at the time of consent (ie, screening), or according to local regulatory requirement if the legal age for consenting for study participation is more than 18 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum_age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "local_regulatory_minimum_age",
                            "expected_value": "if the legal age for consenting for study participation is more than 18 years, use that age"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) 0 or 1.",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) 0 or 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Absolute neutrophil count ≥1,500 cells/μL",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count ≥1,500 cells/μL",
                    "criterion": "absolute neutrophil count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "cells/μL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Life expectancy ≥12 weeks as judged by the Investigator.",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy ≥12 weeks",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "as judged by the Investigator",
                    "criterion": "investigator judgment of life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "assessment",
                            "expected_value": "investigator judgment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically or cytologically documented advanced solid tumor for which no effective standard therapy exists, or standard therapy has failed (Phase 1a).",
            "criterions": [
                {
                    "exact_snippets": "Histologically or cytologically documented advanced solid tumor",
                    "criterion": "advanced solid tumor",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "documentation method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "for which no effective standard therapy exists, or standard therapy has failed (Phase 1a)",
                    "criterion": "standard therapy for advanced solid tumor",
                    "requirements": [
                        {
                            "requirement_type": "effectiveness or failure",
                            "expected_value": [
                                "no effective standard therapy exists",
                                "standard therapy has failed"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Completion of radiotherapy at least 14 days prior to the start of treatment with resolution of any toxicity to maximum Grade 1",
            "criterions": [
                {
                    "exact_snippets": "Completion of radiotherapy at least 14 days prior to the start of treatment",
                    "criterion": "radiotherapy completion",
                    "requirements": [
                        {
                            "requirement_type": "time since completion",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "resolution of any toxicity to maximum Grade 1",
                    "criterion": "toxicity",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "Grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically or cytologically documented advanced solid tumor for which no effective standard therapy exists, and for which standard therapy containing an anti-PD-(L)1 agent has failed after an initial response or stabilization of at least 4-month duration (Phase 1b and 2a).",
            "criterions": [
                {
                    "exact_snippets": "Histologically or cytologically documented advanced solid tumor",
                    "criterion": "advanced solid tumor",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis_method",
                            "expected_value": [
                                "histologically documented",
                                "cytologically documented"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "no effective standard therapy exists",
                    "criterion": "effective standard therapy",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "standard therapy containing an anti-PD-(L)1 agent has failed after an initial response or stabilization of at least 4-month duration",
                    "criterion": "standard therapy containing an anti-PD-(L)1 agent",
                    "requirements": [
                        {
                            "requirement_type": "failure_after_response_or_stabilization",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "initial_response_or_stabilization_duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "month"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. International normalized ratio <1.5 × the upper limit of normal (ULN)",
            "criterions": [
                {
                    "exact_snippets": "International normalized ratio <1.5 × the upper limit of normal (ULN)",
                    "criterion": "international normalized ratio (INR)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "× ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Estimated creatinine clearance >60 mL/min according to the Cockcroft-Gault formula",
            "criterions": [
                {
                    "exact_snippets": "Estimated creatinine clearance >60 mL/min according to the Cockcroft-Gault formula",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "estimation method",
                            "expected_value": "Cockcroft-Gault formula"
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 60,
                                "unit": "mL/min"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Unwilling to stop use of herbal supplements or traditional herbal medicines.",
            "criterions": [
                {
                    "exact_snippets": "Unwilling to stop use of herbal supplements or traditional herbal medicines",
                    "criterion": "use of herbal supplements or traditional herbal medicines",
                    "requirements": [
                        {
                            "requirement_type": "willingness to stop",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Moderate or severe heart valve function defect including moderate or severe valve stenosis or regurgitation.",
            "criterions": [
                {
                    "exact_snippets": "Moderate or severe heart valve function defect",
                    "criterion": "heart valve function defect",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": [
                                "moderate",
                                "severe"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "moderate or severe valve stenosis",
                    "criterion": "valve stenosis",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": [
                                "moderate",
                                "severe"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "moderate or severe ... regurgitation",
                    "criterion": "valve regurgitation",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": [
                                "moderate",
                                "severe"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Use of oral, inhaled, or topical corticosteroid, at doses > 10mg/day prednisolone or equivalent and the dose must be stable over 4 weeks prior to Day1 of Cycle1.",
            "criterions": [
                {
                    "exact_snippets": "Use of oral, inhaled, or topical corticosteroid",
                    "criterion": "corticosteroid use",
                    "requirements": [
                        {
                            "requirement_type": "route of administration",
                            "expected_value": [
                                "oral",
                                "inhaled",
                                "topical"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "doses > 10mg/day prednisolone or equivalent",
                    "criterion": "corticosteroid dose",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "mg/day prednisolone or equivalent"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "the dose must be stable over 4 weeks prior to Day1 of Cycle1",
                    "criterion": "corticosteroid dose stability",
                    "requirements": [
                        {
                            "requirement_type": "stability duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks prior to Day1 of Cycle1"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Congestive heart failure of New York Heart Association class III/IV.",
            "criterions": [
                {
                    "exact_snippets": "Congestive heart failure of New York Heart Association class III/IV",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": [
                                "New York Heart Association class III",
                                "New York Heart Association class IV"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Undergone major surgeries within 28 days of first dosing, or have a planned surgery during the study period.",
            "criterions": [
                {
                    "exact_snippets": "Undergone major surgeries within 28 days of first dosing",
                    "criterion": "major surgeries",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "timing_reference",
                            "expected_value": "before first dosing"
                        }
                    ]
                },
                {
                    "exact_snippets": "planned surgery during the study period",
                    "criterion": "surgery",
                    "requirements": [
                        {
                            "requirement_type": "planned",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing_reference",
                            "expected_value": "during the study period"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of cardiac or aortic surgery within 6 months prior to screening.",
            "criterions": [
                {
                    "exact_snippets": "History of cardiac or aortic surgery within 6 months prior to screening.",
                    "criterion": "history of cardiac surgery",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to screening"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "History of cardiac or aortic surgery within 6 months prior to screening.",
                    "criterion": "history of aortic surgery",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to screening"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Major arrhythmia or abnormalities identified by ECG per Investigator's judgment.",
            "criterions": [
                {
                    "exact_snippets": "Major arrhythmia",
                    "criterion": "arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "major"
                        }
                    ]
                },
                {
                    "exact_snippets": "abnormalities identified by ECG",
                    "criterion": "ECG abnormalities",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "per Investigator's judgment",
                    "criterion": "Investigator's judgment",
                    "requirements": [
                        {
                            "requirement_type": "assessment",
                            "expected_value": "per Investigator's judgment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Receipt of any live vaccine or live-attenuated vaccine within 30 days prior to the first drug administration and while participating the study.",
            "criterions": [
                {
                    "exact_snippets": "Receipt of any live vaccine or live-attenuated vaccine within 30 days prior to the first drug administration",
                    "criterion": "receipt of live or live-attenuated vaccine",
                    "requirements": [
                        {
                            "requirement_type": "time since receipt",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Receipt of any live vaccine or live-attenuated vaccine ... while participating the study",
                    "criterion": "receipt of live or live-attenuated vaccine",
                    "requirements": [
                        {
                            "requirement_type": "receipt during study participation",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female patients who are breastfeeding.",
            "criterions": [
                {
                    "exact_snippets": "Female patients who are breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "breastfeeding"
                        }
                    ]
                }
            ]
        },
        {
            "line": "For Anti PD1 antibody combination therapy part:",
            "criterions": [
                {
                    "exact_snippets": "Anti PD1 antibody combination therapy part",
                    "criterion": "treatment part",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": "Anti PD1 antibody combination therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known substance abuse concurrent treatment with non-permitted drugs.",
            "criterions": [
                {
                    "exact_snippets": "Known substance abuse",
                    "criterion": "substance abuse",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "concurrent treatment with non-permitted drugs",
                    "criterion": "treatment with non-permitted drugs",
                    "requirements": [
                        {
                            "requirement_type": "concurrent treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Myocardial infarction within 6 months prior to screening, or pericardial effusion.",
            "criterions": [
                {
                    "exact_snippets": "Myocardial infarction within 6 months prior to screening",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to screening"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "pericardial effusion",
                    "criterion": "pericardial effusion",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Elevated troponin 1 levels (Grade 3) at screening or known to have persistently elevated brain natriuretic peptide.",
            "criterions": [
                {
                    "exact_snippets": "Elevated troponin 1 levels (Grade 3) at screening",
                    "criterion": "troponin 1 levels",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "Grade 3"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at screening"
                        },
                        {
                            "requirement_type": "level",
                            "expected_value": "elevated"
                        }
                    ]
                },
                {
                    "exact_snippets": "known to have persistently elevated brain natriuretic peptide",
                    "criterion": "brain natriuretic peptide",
                    "requirements": [
                        {
                            "requirement_type": "level",
                            "expected_value": "persistently elevated"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of severe bleeding. Unable to stop anticoagulation therapy with heparin, low molecular weight heparin, vitamin K antagonists, antiplatelet agents, or factor Xa inhibitors throughout the study and for at least 28 days after the last administration of study treatment.",
            "criterions": [
                {
                    "exact_snippets": "History of severe bleeding",
                    "criterion": "severe bleeding",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Unable to stop anticoagulation therapy with heparin, low molecular weight heparin, vitamin K antagonists, antiplatelet agents, or factor Xa inhibitors throughout the study and for at least 28 days after the last administration of study treatment",
                    "criterion": "anticoagulation therapy",
                    "requirements": [
                        {
                            "requirement_type": "ability to stop therapy",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "therapy agents",
                            "expected_value": [
                                "heparin",
                                "low molecular weight heparin",
                                "vitamin K antagonists",
                                "antiplatelet agents",
                                "factor Xa inhibitors"
                            ]
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "throughout the study and for at least 28 days after the last administration of study treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female patients must not be pregnant or at risk to become pregnant during the study. Fertile male and female patients must agree to use an effective barrier method of birth control to avoid pregnancy (for female patients a double-barrier method of contraception, for male patients a condom with spermicide) or total abstinence from the time of providing informed consent until 30 days after the last administration of TU2218.",
            "criterions": [
                {
                    "exact_snippets": "Female patients must not be pregnant",
                    "criterion": "pregnancy status (female)",
                    "requirements": [
                        {
                            "requirement_type": "pregnancy",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Female patients must not be ... at risk to become pregnant during the study",
                    "criterion": "risk of pregnancy (female)",
                    "requirements": [
                        {
                            "requirement_type": "risk of pregnancy during the study",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Fertile male and female patients must agree to use an effective barrier method of birth control to avoid pregnancy (for female patients a double-barrier method of contraception, for male patients a condom with spermicide) or total abstinence from the time of providing informed consent until 30 days after the last administration of TU2218.",
                    "criterion": "contraception use (fertile male and female)",
                    "requirements": [
                        {
                            "requirement_type": "contraception method",
                            "expected_value": [
                                "effective barrier method",
                                "total abstinence"
                            ]
                        },
                        {
                            "requirement_type": "contraception duration",
                            "expected_value": "from informed consent until 30 days after last administration of TU2218"
                        }
                    ]
                },
                {
                    "exact_snippets": "for female patients a double-barrier method of contraception",
                    "criterion": "contraception method (female)",
                    "requirements": [
                        {
                            "requirement_type": "contraception method",
                            "expected_value": "double-barrier method"
                        }
                    ]
                },
                {
                    "exact_snippets": "for male patients a condom with spermicide",
                    "criterion": "contraception method (male)",
                    "requirements": [
                        {
                            "requirement_type": "contraception method",
                            "expected_value": "condom with spermicide"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uncontrolled hypertension (as defined by systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg) during the screening period.",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled hypertension (as defined by systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg) during the screening period",
                    "criterion": "hypertension",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "systolic blood pressure ≥160 mmHg",
                    "criterion": "systolic blood pressure",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 160,
                                "unit": "mmHg"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "diastolic blood pressure ≥100 mmHg",
                    "criterion": "diastolic blood pressure",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100,
                                "unit": "mmHg"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any other serious medical condition which in the Investigator's opinion would preclude safe participation in the study.",
            "criterions": [
                {
                    "exact_snippets": "Any other serious medical condition ... would preclude safe participation in the study.",
                    "criterion": "serious medical condition",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "serious"
                        },
                        {
                            "requirement_type": "impact on study participation",
                            "expected_value": "would preclude safe participation"
                        }
                    ]
                },
                {
                    "exact_snippets": "in the Investigator's opinion",
                    "criterion": "Investigator's opinion",
                    "requirements": [
                        {
                            "requirement_type": "assessment",
                            "expected_value": "Investigator's discretion"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Unable or unwilling to stop use of gastric pH elevating agents including proton pump inhibitors, H2-recpetor antagonists and antacide at least 8 days prior to study entry (Day 1) or within all dose escalation cohorts.",
            "criterions": [
                {
                    "exact_snippets": "Unable or unwilling to stop use of gastric pH elevating agents including proton pump inhibitors, H2-recpetor antagonists and antacide at least 8 days prior to study entry (Day 1) or within all dose escalation cohorts.",
                    "criterion": "use of gastric pH elevating agents",
                    "requirements": [
                        {
                            "requirement_type": "cessation prior to study entry",
                            "expected_value": {
                                "operator": ">=",
                                "value": 8,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "willingness to stop",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known history, or suspected hypersensitivity to any excipients of the clinical study drugs.",
            "criterions": [
                {
                    "exact_snippets": "Known history, or suspected hypersensitivity to any excipients of the clinical study drugs.",
                    "criterion": "hypersensitivity to excipients of the clinical study drugs",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active autoimmune disease or history of autoimmune disease, except vitiligo, hypothyroidism, or resolved childhood asthma/atropy",
            "criterions": [
                {
                    "exact_snippets": "Active autoimmune disease",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "history of autoimmune disease",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "except vitiligo, hypothyroidism, or resolved childhood asthma/atropy",
                    "criterion": "autoimmune disease subtype",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": [
                                "vitiligo",
                                "hypothyroidism",
                                "resolved childhood asthma/atropy"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uncontrolled metastatic disease to the brain or central nervous system, massive uncontrolled effusions (pleural, pericardial, peritoneal), pulmonary lymphangitis, and over 50% liver involvement that is at the discretion of the Investigator. Note: Pleural effusion should be defined by Investigator's discretion.",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled metastatic disease to the brain or central nervous system",
                    "criterion": "metastatic disease to the brain or central nervous system",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "massive uncontrolled effusions (pleural, pericardial, peritoneal)",
                    "criterion": "effusions (pleural, pericardial, peritoneal)",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "massive"
                        },
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "pulmonary lymphangitis",
                    "criterion": "pulmonary lymphangitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "over 50% liver involvement",
                    "criterion": "liver involvement",
                    "requirements": [
                        {
                            "requirement_type": "extent",
                            "expected_value": {
                                "operator": ">",
                                "value": 50,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known tolerance to an anti-PD(L)1 agent during prior exposure",
            "criterions": [
                {
                    "exact_snippets": "Known tolerance to an anti-PD(L)1 agent during prior exposure",
                    "criterion": "tolerance to anti-PD(L)1 agent",
                    "requirements": [
                        {
                            "requirement_type": "tolerance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "during prior exposure"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active infection requiring systemic antibiotic therapy.",
            "criterions": [
                {
                    "exact_snippets": "Active infection requiring systemic antibiotic therapy",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "systemic antibiotic therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Tumor that compresses or invades major blood vessels or tumor cavitation that in the opinion of the Investigator is likely to bleed.",
            "criterions": [
                {
                    "exact_snippets": "Tumor that compresses or invades major blood vessels",
                    "criterion": "tumor involvement with major blood vessels",
                    "requirements": [
                        {
                            "requirement_type": "compression or invasion",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "tumor cavitation that in the opinion of the Investigator is likely to bleed",
                    "criterion": "tumor cavitation likely to bleed",
                    "requirements": [
                        {
                            "requirement_type": "likelihood of bleeding (per Investigator)",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Unstable angina pectoris, cerebrovascular accident, transient ischemic attack, or symptomatic pulmonary embolism; deep venous thrombosis; arterial occlusive disease in the past 12 months.",
            "criterions": [
                {
                    "exact_snippets": "Unstable angina pectoris ... in the past 12 months.",
                    "criterion": "unstable angina pectoris",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "cerebrovascular accident ... in the past 12 months.",
                    "criterion": "cerebrovascular accident",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "transient ischemic attack ... in the past 12 months.",
                    "criterion": "transient ischemic attack",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "symptomatic pulmonary embolism ... in the past 12 months.",
                    "criterion": "symptomatic pulmonary embolism",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "deep venous thrombosis ... in the past 12 months.",
                    "criterion": "deep venous thrombosis",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "arterial occlusive disease in the past 12 months.",
                    "criterion": "arterial occlusive disease",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active and clinically significant bacterial, fungal, or viral infection, including active or known history of hepatitis B virus (defined as hepatitis B surface antigen [HbsAg] reactive), or known active hepatitis C virus (defined as hepatitis C virus ribonucleic acid [qualitative] is detected), known human immunodeficiency virus or acquired immunodeficiency syndrome related illness. However, an inactive hepatitis B virus carrier can be enrolled",
            "criterions": [
                {
                    "exact_snippets": "Active and clinically significant bacterial, fungal, or viral infection",
                    "criterion": "clinically significant infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "active or known history of hepatitis B virus (defined as hepatitis B surface antigen [HbsAg] reactive)",
                    "criterion": "hepatitis B virus infection",
                    "requirements": [
                        {
                            "requirement_type": "activity or history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "hepatitis B surface antigen [HbsAg]",
                            "expected_value": "reactive"
                        }
                    ]
                },
                {
                    "exact_snippets": "known active hepatitis C virus (defined as hepatitis C virus ribonucleic acid [qualitative] is detected)",
                    "criterion": "hepatitis C virus infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "hepatitis C virus ribonucleic acid [qualitative]",
                            "expected_value": "detected"
                        }
                    ]
                },
                {
                    "exact_snippets": "known human immunodeficiency virus or acquired immunodeficiency syndrome related illness",
                    "criterion": "HIV or AIDS-related illness",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Unable to stop chronic systemic steroid therapy or any other immunosuppressive mediacation",
            "criterions": [
                {
                    "exact_snippets": "Unable to stop chronic systemic steroid therapy",
                    "criterion": "chronic systemic steroid therapy",
                    "requirements": [
                        {
                            "requirement_type": "ability to stop",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Unable to stop ... any other immunosuppressive mediacation",
                    "criterion": "immunosuppressive medication",
                    "requirements": [
                        {
                            "requirement_type": "ability to stop",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Received prior treatment targeting the signaling pathway of TGF-β.",
            "criterions": [
                {
                    "exact_snippets": "Received prior treatment targeting the signaling pathway of TGF-β",
                    "criterion": "prior treatment targeting the signaling pathway of TGF-β",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Evidence or history of septal aneurysm, other heart aneurysm, or any aneurysm of the major vessels.",
            "criterions": [
                {
                    "exact_snippets": "Evidence or history of septal aneurysm",
                    "criterion": "septal aneurysm",
                    "requirements": [
                        {
                            "requirement_type": "evidence or history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Evidence or history of ... other heart aneurysm",
                    "criterion": "other heart aneurysm",
                    "requirements": [
                        {
                            "requirement_type": "evidence or history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Evidence or history of ... any aneurysm of the major vessels",
                    "criterion": "aneurysm of the major vessels",
                    "requirements": [
                        {
                            "requirement_type": "evidence or history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known history of difficulty swallowing, malabsorption or other conditions that may reduce absorption of the product.",
            "criterions": [
                {
                    "exact_snippets": "Known history of difficulty swallowing",
                    "criterion": "difficulty swallowing",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "malabsorption",
                    "criterion": "malabsorption",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "other conditions that may reduce absorption of the product",
                    "criterion": "conditions that may reduce absorption of the product",
                    "requirements": [
                        {
                            "requirement_type": "potential to reduce absorption",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Regular use of aspirin (>325mg/day) or other non-steroidal anti-inflammatory drugs with antiplatelet activity or treatment with dipyramidole, ticlopidine, clopidogrel, or cilostazol within 10 days of first administration of study treatment.",
            "criterions": [
                {
                    "exact_snippets": "Regular use of aspirin (>325mg/day)",
                    "criterion": "aspirin use",
                    "requirements": [
                        {
                            "requirement_type": "frequency",
                            "expected_value": "regular"
                        },
                        {
                            "requirement_type": "dosage",
                            "expected_value": {
                                "operator": ">",
                                "value": 325,
                                "unit": "mg/day"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "other non-steroidal anti-inflammatory drugs with antiplatelet activity",
                    "criterion": "non-steroidal anti-inflammatory drug (NSAID) use with antiplatelet activity",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "treatment with dipyramidole, ticlopidine, clopidogrel, or cilostazol within 10 days of first administration of study treatment",
                    "criterion": "treatment with dipyramidole, ticlopidine, clopidogrel, or cilostazol",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 10,
                                "unit": "days before first administration of study treatment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Current or history of interstitial pneumonitis.",
            "criterions": [
                {
                    "exact_snippets": "Current or history of interstitial pneumonitis",
                    "criterion": "interstitial pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "presence or history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "* Unable to unwilling to stop use of strong inhibitors of CYP1A2, CYP2C8, and CYP3A4, and strong inhibitors of P-gp and BCRP at least 8 days prior to study entry (Day 1) or within all dose escalation cohorts.",
            "criterions": [
                {
                    "exact_snippets": "Unable to unwilling to stop use of strong inhibitors of CYP1A2, CYP2C8, and CYP3A4, and strong inhibitors of P-gp and BCRP at least 8 days prior to study entry (Day 1) or within all dose escalation cohorts.",
                    "criterion": "use of strong inhibitors of CYP1A2",
                    "requirements": [
                        {
                            "requirement_type": "cessation prior to study entry",
                            "expected_value": {
                                "operator": ">=",
                                "value": 8,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Unable to unwilling to stop use of strong inhibitors of CYP2C8",
                    "criterion": "use of strong inhibitors of CYP2C8",
                    "requirements": [
                        {
                            "requirement_type": "cessation prior to study entry",
                            "expected_value": {
                                "operator": ">=",
                                "value": 8,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Unable to unwilling to stop use of strong inhibitors of CYP3A4",
                    "criterion": "use of strong inhibitors of CYP3A4",
                    "requirements": [
                        {
                            "requirement_type": "cessation prior to study entry",
                            "expected_value": {
                                "operator": ">=",
                                "value": 8,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Unable to unwilling to stop use of strong inhibitors of P-gp",
                    "criterion": "use of strong inhibitors of P-gp",
                    "requirements": [
                        {
                            "requirement_type": "cessation prior to study entry",
                            "expected_value": {
                                "operator": ">=",
                                "value": 8,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Unable to unwilling to stop use of strong inhibitors of ... BCRP",
                    "criterion": "use of strong inhibitors of BCRP",
                    "requirements": [
                        {
                            "requirement_type": "cessation prior to study entry",
                            "expected_value": {
                                "operator": ">=",
                                "value": 8,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}